98010-51-6

Basic information

• Product Name: Pyrazinecarboxylic acid, 2-[(phenylamino)thioxomethyl]hydrazide
• CAS NO: 98010-51-6
• Molecular Formula: C12H11N5OS
• Molecular Weight: 273.318
• Mol File: 98010-51-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Pyrazinecarboxylic acid, 2-[(phenylamino)thioxomethyl]hydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazinecarboxylic acid, 2-[(phenylamino)thioxomethyl]hydrazide(98010-51-6)
• EPA Substance Registry System: Pyrazinecarboxylic acid, 2-[(phenylamino)thioxomethyl]hydrazide(98010-51-6)

Safety Data

• Hazardous Substances Data: 98010-51-6(Hazardous Substances Data)

Upstream product

• 6924-68-1 ethyl 2-pyrazinecarboxylate 
• 6164-79-0 methyl pyrazine-2-carboxylate 
• 98-97-5 2-pyrazylcarboxylic acid 
• 768-05-8 pyrazine-2-carbohydrazide 
• 103-72-0 phenyl isothiocyanate 
• 5285-87-0 phenyl thiocyanate 

Downstream Products

• 1404052-61-4 C₁₉H₁₄FN₅S 
• 1404052-62-5 C₁₉H₁₄ClN₅S 
• 1404052-63-6 C₁₉H₁₄BrN₅S 
• 1404052-64-7 C₁₉H₁₄ClN₅S 
• 1404052-65-8 C₁₉H₁₄BrN₅S 
• 1404052-66-9 C₁₉H₁₄ClN₅S 
• 1404052-67-0 C₁₉H₁₃F₂N₅S 
• 874454-79-2 2-(5-((2,6-difluorobenzyl)thio)-4-phenyl-4H-1,2,4-triazol-3-yl)pyrazine 
• 98010-64-1 C₁₉H₁₅N₅S 
• 98010-52-7 C₁₂H₉N₅S 
• 1422706-94-2 N-phenyl-5-(pyrazin-2-yl)-1,3,4-oxadiazole-2-amine 

Relevant articles and documents

Tryptophan and thiosemicarbazide derivatives: Design, synthesis, and biological evaluation as potential β-D-galactosidase and β-D-glucosidase inhibitors

Glycosidases, including β-D-galactosidase and β-D-glucosidase, are involved in a range of metabolic disorders, such as cancer, viral or bacterial infections, and diabetes. Previously, we scanned the pharmacophoric space of these enzymes and had a self-consistent and predictive quantitative structure-activity relationship that was used to identify several β-D-galactosidase and β-D-glucosidase inhibitors via in silico search of structural databases. Guided by the preceding modeling efforts, synthesis of a series of tryptophan and thiosemicarbazide derivatives as β-D-galactosidase and β-D-glucosidase inhibitors that match the generated pharmacophores followed by in vitro bioassay was carried out. Synthesized compounds 3c (37 % inhibition at 100 μM) and 4d (49 % inhibition at 100 μM) exhibited the best inhibitory bioactivities against β-D-galactosidase and β-D-glucosidase, respectively. They can serve as a promising lead compounds for the development of potential glycosidase inhibitors.

Design, synthesis and biological evaluation of heterocyclic azoles derivatives containing pyrazine moiety as potential telomerase inhibitors

Three series of novel heterocyclic azoles derivatives containing pyrazine (5a-5k, 8a-8k and 11a-11k) have been designed, synthesized, structurally determined, and their biological activities were evaluated as potential telomerase inhibitors. Among the oxadiazole derivatives, compound 5c showed the most potent biological activity against SW1116 cancer cell line (IC50 = 2.46 μM against SW1116 and IC50 = 3.55 μM for telomerase). Compound 8h performed the best in the thiadiazole derivatives (IC50 = 0.78 μM against HEPG2 and IC50 = 1.24 μM for telomerase), which was comparable to the positive control. While compound 11f showed the most potent biological activity (IC50 = 4.12 μM against SW1116 and IC50 = 15.03 μM for telomerase) among the triazole derivatives. Docking simulation by positioning compounds 5c, 8h and 11f into the telomerase structure active site was performed to explore the possible binding model. The results of apoptosis demonstrated that compound 8h possessed good antitumor activity against HEPG2 cancer cell line. Therefore, compound 8h with potent inhibitory activity in tumor growth inhibition may be a potential antitumor agent against HEPG2 cancer cell. Therefore, the introduction of oxadiazole, thiadiazole and triazole structures reinforced the combination of our compounds and the receptor, resulting in progress of bioactivity.